To assist with virtual learning during the COVID-19 pandemic, we’d like to remind you of the valuable resources NIGMS supports for our trainee and educator communities. These resources apply to all levels, ranging from community college students to faculty.

UPDATE: Figure 2 of this post was updated slightly in March 2021 to reflect NIGMS-supported Early Stage Investigator counts more accurately.

On December 20, 2019, the Further Consolidated Appropriations Act, 2020, was signed into law. The appropriation provides NIGMS with a budget of $2,937,218,000 in Fiscal Year (FY) 2020, a 2.2% increase over the FY 2019 appropriation. With this increased budget, NIGMS is committed to providing taxpayers with the best possible returns on their investments in fundamental biomedical research. As part of this commitment to stewardship, we regularly monitor trends in our funding portfolio.

NIGMS maintains a diversified investment portfolio, supporting a wide range of research topics and investigators. Recent NIGMS and NIH programs and policies aim to increase the number of different investigators funded, and to maintain researchers’ funding stability over time. Consistent with our focus on supporting a broad group of investigators, we monitor two statistics that describe our investigator pool.

I’m pleased to announce that Erica Brown has been named NIGMS associate director for extramural activities and director of our Division of Extramural Activities (DEA). In this role, Erica oversees the receipt, referral, review, and fiscal management of the Institute’s grants. Additionally, she serves as executive secretary of our advisory council and advises senior staff on the planning, development, and administration of Institute grant activities.

It’s with profoundly mixed emotions that I tell you that Susan Gregurick has been named the NIH associate director for data science and director of the Office of Data Science Strategy. This new position will allow her to play a key role in shaping data science activities across NIH.

Susan has provided extraordinary leadership to our Division of Biophysics, Biomedical Technology, and Computational Biosciences (BBCB) for the past 6 years and has been an essential member of the Institute’s senior staff. I’m confident that she’ll bring the same level of enthusiasm, professionalism, judgment, and keen intellect to her new office as she did here at NIGMS. The appointment becomes official on September 15, although Susan will remain here at NIGMS through the end of the month. Deputy Director Judith Greenberg will serve as acting director of BBCB while we search for a permanent replacement.

For more on this appointment, see the statement from NIH Director Francis Collins. Please join me in wishing Susan the best in the next phase of her career. NIGMS’ loss is certainly NIH’s gain!

I’m pleased to congratulate four members of the NIGMS community who are among the recipients of the 2019 Presidential Early Career Award for Scientists and Engineers. This award is the highest honor bestowed by the United States government to outstanding scientists and engineers who are beginning their independent research careers and who show exceptional promise for leadership in science and technology.

On June 12, NIH Director Francis Collins announced that he will not take part in conferences or meetings in which “attention to inclusiveness is not evident in the agenda.” In keeping with this announcement, all NIGMS staff, including leadership, program and scientific review officers, grants management specialists, and others, will only attend meetings and conferences where the organizers have shown a strong commitment to diversity and inclusion in their selection of chairs, speakers, and panelists. NIGMS has a long-standing mission to promote diversity in the scientific enterprise. Helping to ensure that the organizers of scientific conferences and meetings plan diverse and inclusive agendas will further our goal of developing the most creative, vibrant, and productive biomedical research workforce possible.

For the past few months, NIGMS has been reviewing its HIV/AIDS grant portfolio. As the HIV/AIDS field has matured and the necessary research directions have become clearer, the HIV/AIDS-related grants we’ve supported have, appropriately, become more narrowly focused. Because of this, and after close consultation with leadership at the National Institute of Allergy and Infectious Diseases (NIAID), we’ve concluded that it’s in the best interest of the research to transition NIGMS’ HIV/AIDS portfolio to NIAID to allow improved scientific coordination, prioritization, and efficiency of management.

UPDATE: Figure 2 of this post was updated slightly in March 2021 to reflect NIGMS-supported Early Stage Investigator counts more accurately.

On September 28, 2018, the Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 was signed into law. The law includes an NIGMS budget of $2,872,780,000 for Fiscal Year (FY) 2019—a 3.1% increase from FY 2018. This budget increase follows a 5.1% rise in funding in FY 2018.

NIGMS is committed to ensuring that taxpayers get the best possible returns on their investments in fundamental biomedical research . As part of this commitment to stewardship, we regularly monitor trends in our funding portfolio.

I’m pleased to announce the debut of Pathways, a collaboration between NIGMS and Scholastic, Inc., that provides a collection of free educational resources about basic biomedical science and research careers.

As we work on issuing a new funding opportunity announcement (FOA) for the established investigator (EI) MIRA program, we thought it would be useful to address a few common questions we’ve been hearing. The new FOA will allow applications from NIGMS grantees who have one or more single-Principal Investigator (PI) R01-equivalent awards, just as the current FOA does. In addition, the new FOA (to be published by Fall 2019) will allow renewal applications from PIs who already have MIRA grants.